| scholarly article | Q13442814 |
| P50 | author | Maria Grazia Spillantini | Q15994759 |
| Trevor Humby | Q57713073 | ||
| Pablo Garcia-Reitböck | Q84377830 | ||
| George K Tofaris | Q56056700 | ||
| Bernardino F. Ghetti | Q56863342 | ||
| P2093 | author name string | Michel Goedert | |
| Lawrence S Wilkinson | |||
| Piers C Emson | |||
| Mark O'Connell | |||
| Helen Gossage | |||
| Sarah L Lambourne | |||
| P2860 | cites work | Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies | Q24554351 |
| α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies | Q24653247 | ||
| Deletion of the alpha-synuclein locus in a subpopulation of C57BL/6J inbred mice | Q24805405 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| α-Synuclein in Lewy bodies | Q27860680 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Alpha-synuclein and neurodegenerative diseases | Q28204386 | ||
| Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain | Q28509158 | ||
| Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein | Q28587358 | ||
| Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor | Q28588013 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies | Q57982456 | ||
| Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein | Q73815124 | ||
| Neuropathology in mice expressing human alpha-synuclein | Q74139704 | ||
| Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease | Q80794093 | ||
| ??? | Q64767196 | ||
| AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease | Q29547175 | ||
| Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders | Q29614754 | ||
| Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
| Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice | Q30476254 | ||
| Characterisation of isolated alpha-synuclein filaments from substantia nigra of Parkinson's disease brain | Q33181095 | ||
| Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations | Q33836384 | ||
| alpha-Synuclein is phosphorylated in synucleinopathy lesions | Q34111460 | ||
| Identification of two distinct synucleins from human brain | Q34341909 | ||
| Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation | Q35700288 | ||
| Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model | Q35747138 | ||
| Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies | Q35764504 | ||
| Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies | Q35791524 | ||
| Olfaction and Parkinson's syndromes: its role in differential diagnosis | Q35833220 | ||
| Endoproteolytic activity of the proteasome | Q36450745 | ||
| A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease | Q40433173 | ||
| NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. | Q40921912 | ||
| Neuropathology of Parkinson's disease | Q41095404 | ||
| Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease | Q41693341 | ||
| Polycation-induced oligomerization and accelerated fibrillation of human alpha-synuclein in vitro | Q41849419 | ||
| Effect of p-chlorophenylalanine on release of 5-hydroxytryptamine from the rat frontal cortex in vivo | Q42025574 | ||
| Biochemical aspects of Parkinson's disease | Q42460123 | ||
| Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice | Q43612913 | ||
| Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter | Q43665738 | ||
| alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome | Q43816254 | ||
| Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice | Q43992501 | ||
| D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. | Q44037073 | ||
| Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum | Q44106399 | ||
| Cellular polyamines promote the aggregation of alpha-synuclein | Q44219245 | ||
| Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro | Q44530279 | ||
| Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function | Q44552114 | ||
| Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice | Q44791898 | ||
| Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations. | Q46427562 | ||
| Early-onset dementia with Lewy bodies | Q47357514 | ||
| Role of alpha-synuclein carboxy-terminus on fibril formation in vitro | Q47762431 | ||
| Epitope mapping and specificity of the anti-alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines | Q48214340 | ||
| Synthetic filaments assembled from C‐terminally truncated α‐synuclein | Q48360396 | ||
| Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies | Q48401512 | ||
| Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases | Q48494226 | ||
| Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein | Q48581887 | ||
| Common genetic effects on variation in impulsivity and activity in mice. | Q52088384 | ||
| Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage | Q53875651 | ||
| 5' upstream DNA sequence of the rat tyrosine hydroxylase gene directs high-level and tissue-specific expression to catecholaminergic neurons in the central nervous system of transgenic mice. | Q54622830 | ||
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | dopamine | Q170304 |
| olfactory bulb | Q644945 | ||
| substantia nigra | Q753278 | ||
| Synuclein | Q24767155 | ||
| P304 | page(s) | 3942-3950 | |
| P577 | publication date | 2006-04-01 | |
| P1433 | published in | Journal of Neuroscience | Q1709864 |
| P1476 | title | Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders | |
| P478 | volume | 26 |
| Q48278741 | 100 years of Lewy pathology |
| Q47548619 | A Protein Aggregation Inhibitor, Leuco-Methylthioninium Bis(Hydromethanesulfonate), Decreases α-Synuclein Inclusions in a Transgenic Mouse Model of Synucleinopathy |
| Q37472304 | A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease |
| Q37407288 | A phenotypic model recapitulating the neuropathology of Parkinson's disease |
| Q43247253 | A progressive dopaminergic phenotype associated with neurotoxic conversion of α-synuclein in BAC-transgenic rats |
| Q27324171 | A53T-alpha-synuclein overexpression impairs dopamine signaling and striatal synaptic plasticity in old mice |
| Q34358218 | Abnormal neurites containing C-terminally truncated alpha-synuclein are present in Alzheimer's disease without conventional Lewy body pathology. |
| Q57285629 | Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson's Disease |
| Q35698432 | Accelerated formation of alpha-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations |
| Q38966914 | Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo |
| Q64764794 | Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice |
| Q52678048 | Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. |
| Q37401007 | Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells |
| Q55152170 | Alpha-Synuclein: From Early Synaptic Dysfunction to Neurodegeneration. |
| Q38101508 | Alpha-synuclein and intracellular trafficking: impact on the spreading of Parkinson's disease pathology. |
| Q89518306 | Alpha-synuclein fragments trigger distinct aggregation pathways |
| Q42320467 | Alpha-synuclein prevents the formation of spherical mitochondria and apoptosis under oxidative stress |
| Q37187907 | An optogenetic mouse model of rett syndrome targeting on catecholaminergic neurons |
| Q90396705 | Animal Model for Prodromal Parkinson's Disease |
| Q36924624 | Animal models of Parkinson's disease progression |
| Q36454426 | Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. |
| Q57143848 | Animal models of neurodegenerative diseases |
| Q40106906 | Animal models of α-synucleinopathy for Parkinson disease drug development |
| Q35923102 | Axon degeneration in Parkinson's disease |
| Q41475139 | Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders |
| Q36658992 | Axonopathy in an α-Synuclein Transgenic Model of Lewy Body Disease Is Associated with Extensive Accumulation of C-Terminal–Truncated α-Synuclein |
| Q35757239 | Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation |
| Q37237452 | Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration |
| Q52624714 | Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease? |
| Q37102231 | Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo. |
| Q40085533 | Cellular oligomerization of alpha-synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence |
| Q37294051 | Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons |
| Q33894382 | Critical Role of Truncated α‐Synuclein and Aggregates in Parkinson's Disease and Incidental Lewy Body Disease |
| Q40226743 | Cytosolic catechols inhibit alpha-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. |
| Q92529012 | Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model |
| Q38624671 | Dimebon does not ameliorate pathological changes caused by expression of truncated (1-120) human alpha-synuclein in dopaminergic neurons of transgenic mice. |
| Q55715226 | Dopamine Transporter/α-Synuclein Complexes Are Altered in the Post Mortem Caudate Putamen of Parkinson's Disease: An In Situ Proximity Ligation Assay Study. |
| Q46657177 | Dopaminergic lesioning impairs adult hippocampal neurogenesis by distinct modification of α-synuclein |
| Q60932604 | Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies |
| Q42439876 | Electrophysiology and pharmacology of striatal neuronal dysfunction induced by mitochondrial complex I inhibition |
| Q64791351 | Emerging Immunotherapies for Parkinson Disease. |
| Q42740346 | Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra |
| Q37706391 | Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease. |
| Q26772843 | Evaluation of Models of Parkinson's Disease |
| Q46314161 | Exogenous α-Synuclein Monomers Alter Dopamine Metabolism in Murine Brain |
| Q28388674 | Gene-environment interactions: key to unraveling the mystery of Parkinson's disease |
| Q37796009 | Genetic mouse models of Parkinson's disease The state of the art. |
| Q26852964 | Genetically engineered mouse models of Parkinson's disease |
| Q30620210 | Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice |
| Q40150743 | Hippocampal neuronal cells that accumulate α-synuclein fragments are more vulnerable to Aβ oligomer toxicity via mGluR5--implications for dementia with Lewy bodies |
| Q93357641 | Immune system responses in Parkinson's disease: Early and dynamic |
| Q36976137 | In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? |
| Q46252300 | In vivo models of alpha-synuclein transmission and propagation. |
| Q36607413 | Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease |
| Q61799784 | Inhalation of hydrogen gas elevates urinary 8-hydroxy-2'-deoxyguanine in Parkinson's disease |
| Q34732028 | Intact olfaction in a mouse model of multiple system atrophy. |
| Q35834043 | Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease |
| Q26801733 | Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease? |
| Q36512589 | Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type α-Synuclein and Reduces the Pathology in an α-Synuclein Model of LBD |
| Q41488512 | Limitations of Animal Models of Parkinson's Disease |
| Q55240777 | Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease. |
| Q53448459 | Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease. |
| Q43518984 | Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain |
| Q42095746 | Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies |
| Q38038561 | Lysosome-dependent pathways as a unifying theme in Parkinson's disease. |
| Q34273047 | Mechanisms underlying the impairment of hippocampal long-term potentiation and memory in experimental Parkinson's disease. |
| Q58799080 | Microglia Response During Parkinson's Disease: Alpha-Synuclein Intervention |
| Q38021865 | Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences |
| Q36797994 | Model fusion, the next phase in developing animal models for Parkinson's disease |
| Q94544629 | Modeling Parkinson's Disease With the Alpha-Synuclein Protein |
| Q37957494 | Modelling of Parkinson's disease in mice |
| Q33392127 | Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze? |
| Q37309838 | Molecular mechanisms of alpha-synuclein neurodegeneration |
| Q39930416 | N-terminal region of alpha-synuclein is essential for the fatty acid-induced oligomerization of the molecules. |
| Q38268886 | Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression |
| Q51790795 | Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. |
| Q27027973 | Neuroimmunological Processes in Parkinson’s Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity |
| Q37241917 | Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration |
| Q38122519 | New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson's disease. |
| Q38821744 | Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse |
| Q64242771 | Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease |
| Q42291314 | Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease |
| Q38189727 | Olfactory bulb involvement in neurodegenerative diseases. |
| Q46237585 | Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria |
| Q33947949 | Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice |
| Q42473489 | Overview of mouse models of Parkinson's disease |
| Q37509229 | Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle |
| Q38279732 | Parkinson's disease as a member of Prion-like disorders |
| Q37874160 | Parkinson's disease mouse models in translational research |
| Q47389506 | Parkinson's disease: experimental models and reality |
| Q57458019 | Physiological carboxy-truncation of α-synuclein potentiates the prion-like formation of pathological inclusions |
| Q50692501 | Predominant neuritic pathology induced by viral overexpression of alpha-synuclein in cell culture |
| Q21142674 | Progression of Parkinson's disease pathology is reproduced by intragastric administration of rotenone in mice |
| Q24299645 | Redistribution of DAT/α-synuclein complexes visualized by "in situ" proximity ligation assay in transgenic mice modelling early Parkinson's disease |
| Q37213903 | Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy |
| Q34075948 | Residue histidine 50 plays a key role in protecting α-synuclein from aggregation at physiological pH. |
| Q28477043 | Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation |
| Q37151410 | Review: Familial Parkinson's disease--genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease |
| Q37778899 | Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies |
| Q35510197 | Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. |
| Q33944220 | SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease |
| Q97516927 | SUMOylation in α-Synuclein Homeostasis and Pathology |
| Q38819135 | Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains |
| Q64088424 | Spreading of α-Synuclein and Tau: A Systematic Comparison of the Mechanisms Involved |
| Q58779935 | Stomaching the Possibility of a Pathogenic Role for Helicobacter pylori in Parkinson's Disease |
| Q38154648 | Stress-mediated modulations in dopaminergic system and their subsequent impact on behavioral and oxidative alterations: an update. |
| Q26269871 | Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities |
| Q47720283 | Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases |
| Q41635176 | The ER retention protein RER1 promotes alpha-synuclein degradation via the proteasome |
| Q64102410 | The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson's Diseases |
| Q37693375 | The Synucleinopathies: Twenty Years On. |
| Q28068464 | The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease |
| Q42223328 | The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. |
| Q38139561 | The function of α-synuclein |
| Q38166155 | The role of innate and adaptive immunity in Parkinson's disease |
| Q34890228 | Transgenic animal models of neurodegeneration based on human genetic studies. |
| Q43275554 | Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice |
| Q37403103 | Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation |
| Q35344983 | Ubiquitin ligase Nedd4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway |
| Q37775037 | Understanding the molecular basis of Parkinson's disease, identification of biomarkers and routes to therapy |
| Q30412016 | Value of genetic models in understanding the cause and mechanisms of Parkinson's disease |
| Q37796011 | Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease |
| Q21202835 | alpha-Synuclein and neuronal cell death |
| Q59806475 | α-Synuclein Trafficking in Parkinson's Disease: Insights From Fly and Mouse Models |
| Q38039369 | α-Synuclein and Neuronal Cell Death |
| Q38040282 | α-Synuclein elevation in human neurodegenerative diseases: experimental, pathogenetic, and therapeutic implications. |
| Q39443981 | α-synuclein phosphorylation and truncation are normal events in the adult human brain |
Search more.